INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38701, 7225, 'Chlorambucil', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38702, 7225, 'Chlorambucil', 'Bone Marrow Failure Disorders', 'Chlorambucil can severely suppress bone marrow function.  It induces a slowly progressive lymphopenia and dose-related neutropenia.  Thrombocytopenia and anemia may also occur.  Irreversible bone marrow suppression has been reported and is associated with a total dose of or > 6.5 mg/kg in one course of continuous dosing.  Therapy with chlorambucil should be administered cautiously and at a reduced dosage in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38703, 7225, 'Chlorambucil', 'Hepatic Insufficiency', 'No formal studies have been conducted in patients with hepatic impairment.  As chlorambucil is primarily metabolized in the liver, patients with hepatic impairment should be closely monitored for toxicity.  A dose reduction may be considered in patients with hepatic impairment when treated with chlorambucil.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38704, 7225, 'Chlorambucil', 'Lung Diseases', 'Interstitial pneumonitis and/or fibrosis have been reported during chlorambucil therapy.  Pulmonary complications may not be reversible in all patients.  Patients should be instructed to immediately report signs and symptoms of pulmonary dysfunction such as cough, dyspnea or congestion.  Therapy with chlorambucil should be administered cautiously in patients with or predisposed to pulmonary dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38705, 7225, 'Chlorambucil', 'Seizures', 'An increased risk of seizures has been reported in patients administered high pulse doses of chlorambucil and in children with nephrotic syndromes.  Focal and/or generalized seizures have been reported rarely at daily therapeutic doses. Therapy with chlorambucil should be administered cautiously in patients with a history of seizure disorders or head trauma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38706, 149, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38707, 2499, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38708, 2564, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38709, 7921, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38710, 8231, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38711, 8232, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38712, 9271, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38713, 9313, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38714, 9456, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38715, 16245, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38716, 16307, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38717, 16308, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38718, 18442, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38719, 21029, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38720, 21755, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38721, 22814, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38722, 22816, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38723, 22817, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38724, 24138, 'Chloramphenicol (otic)', 'Bone Marrow Failure Disorders', 'Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible.  The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection.  It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy.  Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued.  A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity.  It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug.  Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy.  Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38725, 149, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38726, 2499, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38727, 2564, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38728, 7921, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38729, 8231, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38730, 8232, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38731, 9271, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38732, 9313, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38733, 9456, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38734, 16245, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38735, 16307, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38736, 16308, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38737, 18442, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38738, 21029, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38739, 21755, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38740, 22814, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38741, 22816, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38742, 22817, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38743, 24138, 'Chloramphenicol (otic)', 'Tympanic Membrane Perforation', 'The use of chloramphenicol otic preparations is contraindicated in patients with a perforated tympanic membrane.  The risk of ototoxicity may be increased if medication enters the middle ear.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38744, 2938, 'Chlordiazepoxide', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38745, 2938, 'Chlordiazepoxide', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38746, 2938, 'Chlordiazepoxide', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38747, 2938, 'Chlordiazepoxide', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38748, 2938, 'Chlordiazepoxide', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38749, 2938, 'Chlordiazepoxide', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38750, 2938, 'Chlordiazepoxide', 'Hypotension', 'Benzodiazepines should not be administered by injection to patients in shock or coma.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38751, 2938, 'Chlordiazepoxide', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38752, 2938, 'Chlordiazepoxide', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38753, 2938, 'Chlordiazepoxide', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38754, 2938, 'Chlordiazepoxide', 'Porphyrias', 'There have been isolated reports associating the use of chlordiazepoxide with exacerbation of porphyria.  Therapy with chlordiazepoxide should be administered cautiously in patients with porphyria.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38755, 24890, 'Chenodeoxycholic acid', 'Liver Diseases', 'Chenodeoxycholic acid is contraindicated in the presence of known hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitis; a gallbladder confirmed as non-visualizing after two consecutive single doses of dye; radiopaque stones; or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary gastrointestinal fistula.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38756, 0, 'Albiglutide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38757, 0, 'Albiglutide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38758, 0, 'Albiglutide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38759, 306, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38760, 2506, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38761, 16253, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38762, 16254, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38763, 22238, 'Chloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38764, 306, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38765, 2506, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38766, 16253, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38767, 16254, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38768, 22238, 'Chloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38769, 306, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38770, 2506, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38771, 16253, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38772, 16254, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38773, 22238, 'Chloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38774, 306, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38775, 2506, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38776, 16253, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38777, 16254, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38778, 22238, 'Chloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38779, 306, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38780, 2506, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38781, 16253, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38782, 16254, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38783, 22238, 'Chloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38784, 306, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38785, 2506, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38786, 16253, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38787, 16254, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38788, 22238, 'Chloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38789, 306, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38790, 2506, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38791, 16253, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38792, 16254, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38793, 22238, 'Chloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38794, 306, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38795, 2506, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38796, 16253, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38797, 16254, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38798, 22238, 'Chloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38799, 306, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38800, 2506, 'Chloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
